Wednesday, October 25, 2023
Medinol has announced the receipt of approval from the United States Food and Drug Administration (FDA) for the EluNIR-PERL™ drug-eluting stent (DES), designed for the treatment of coronary artery disease. EluNIR-PERL represents an advancement building upon the established performance and clinical data of the EluNIR™ DES system. This latest iteration in the EluNIR DES series incorporates four radiopaque markers, two located at each end of the stent, along with a hybrid polymer-metal radiopaque catheter tip.
These distinctive features provide exceptional visibility during percutaneous coronary intervention (PCI) procedures, facilitating navigation through complex anatomies and precise stent placement.
Medinol's introduction of ring technologies to the U.S. emphasizes their commitment to benefiting patients while offering distinct advantages to surgeons. This includes enabling precise stent placement, reducing procedure duration, and minimizing radiation exposure. EluNIR-PERL™ is exclusively accessible in the United States through CoSo Health, an innovative healthcare supply and logistics company that is transforming the distribution and sale of medical devices.
Source: prnewswire.com
